T helper 17 (Th17)-dependent autoimmune responses can develop after heart or lung transplantation and are associated with fibro-obliterative forms of chronic rejection; however, the specific self-antigens involved are typically different from those associated with autoimmune disease. To investigate the basis of these responses, we investigated whether removal of regulatory T cells or blockade of function reveals a similar autoantigen bias. We found that Th17 cells specific for collagen type V (Col V), ka1-tubulin, and vimentin were present in healthy adult peripheral blood mononuclear cells, cord blood, and fetal thymus. Using synthetic peptides and recombinant fragments of the Col V triple helical region (a1[V]), we compared Th17 cells from healthy donors with Th17 cells from Col V-reactive heart and lung patients. Although the latter responded well to a1(V) fragments and peptides in an HLA-DR-restricted fashion, Th17 cells from healthy persons responded in an HLA-DR-restricted fashion to fragments but not to peptides. Col V, ka1-tubulin, and vimentin are preferred targets of a highly conserved, hitherto unknown, preexisting Th17 response that is MHC class II restricted. These data suggest that autoimmunity after heart and lung transplantation may result from dysregulation of an intrinsic mechanism controlling airway and vascular homeostasis.
T helper 17 (Th17)-dependent autoimmune responses can develop after heart or lung transplantation and are associated with fibro-obliterative forms of chronic rejection; however, the specific self-antigens involved are typically different from those associated with autoimmune disease. To investigate the basis of these responses, we investigated whether removal of regulatory T cells or blockade of function reveals a similar autoantigen bias. We found that Th17 cells specific for collagen type V (Col V), ka1-tubulin, and vimentin were present in healthy adult peripheral blood mononuclear cells, cord blood, and fetal thymus. Using synthetic peptides and recombinant fragments of the Col V triple helical region (a1[V]), we compared Th17 cells from healthy donors with Th17 cells from Col V-reactive heart and lung patients. Although the latter responded well to a1(V) fragments and peptides in an HLA-DR-restricted fashion, Th17 cells from healthy persons responded in an HLA-DR-restricted fashion to fragments but not to peptides. Col V, ka1-tubulin, and vimentin are preferred targets of a highly conserved, hitherto unknown, preexisting Th17 response that is MHC class II restricted. These data suggest that autoimmunity after heart and lung transplantation may result from dysregulation of an intrinsic mechanism controlling airway and vascular homeostasis.
Introduction
Organ transplantation is the only definitive treatment for many forms of end-stage cardiac and pulmonary disease (1, 2) . Although advances in the transplantation field have curbed acute rejection through new immunosuppressive drugs and better control of infection and ischemiareperfusion injury, chronic allograft rejection is still a major obstacle. Successful organ transplantation appears to require balanced function of effector T cells (Teffs) and regulatory T cells (Tregs) to prevent the emergence of T helper 17 (Th17)-based fibrosis and fibro-obliterative processes in the allograft (3) . Th17 cells have been strongly associated with autoimmune disease, including lupus (4), rheumatoid arthritis (5, 6) , psoriasis (7, 8) , and multiple sclerosis (9, 10) . In addition, Th17 cells have been found to play a key role in the chronic rejection of lung (11, 12) and heart (13, 14) transplants.
these patients was Th17 mediated because the Col V response depended on IL-17, with variable dependence on interferon c (IFN-c) (11) (12) (13) . Interestingly, tumor necrosis factor a (TNF-a), IL-1b, and purinoceptor P2X7 receptor (P2X7R) function, both on Th17 cells and on monocyte antigen-presenting cells (APCs), were also required for the response to Col V in transplant recipients (13) .
Besides Col V, the other well-characterized self-antigenevoking responses in chronic rejection of lung allografts is ka1-tubulin (18) (19) (20) . It has been reported that both T and B cell reactivity to this antigen predicts bronchiolitis obliterans in both mouse and human lung transplantation (19) . In addition, vimentin, a type III intermediate filament component of mesenchymal cells, has been associated with chronic rejection of cardiac allografts in humans and mice (21, 22) .
Recently, a Treg expressing the 3 0 ,5 0 ectonucleotidase CD39 has emerged as a suppressor of Th17 cells in numerous pathologies (23) (24) (25) (26) . Expressed on approximately 50% of human Tregs, CD39 can suppress both Th1 and Th17 responses (23, 27, 28) . Furthermore, CD39-depleted (CD39 À ) Tregs failed to suppress Th17 responses, implying a critical role for CD39 in Treg control of autoimmune Th17 cells (27, 28) . CD39 + Tregs can rapidly lower levels of extracellular adenosine triphosphate (ATP), decreasing P2X7R signaling and increasing the immunosuppressive purine adenosine (29) (30) (31) . This can lead to less IL-1b production from monocytes and macrophages and reduced Th17-mediated immune responses (32) (3). In healthy persons, Tregs can modulate autoimmune Teff function through suppressive cytokines IL-10, IL-35, and TGF-b (27, 33, 34) . This system of Treg-Th17 balance may be deficient in persons undergoing chronic rejection of heart or lung allograft, as has been reported in kidney allograft models (35) .
Two major questions regarding Th17-mediated autoimmune pathologies remain: (i) Why is Col V, vimentin, or ka1-tubulin-and not the self-antigens commonly associated with autoimmune disease-the focus of transplantinduced autoimmunity? (ii) Is the pathogenic Th17 cell induced in the periphery or is it a preexisting, thymically differentiated Th17 cell that has escaped regulation? In this report, we address the first question by testing the hypothesis that preexisting Th17 and Treg cells specific for Col V, vimentin, and ka1-tubulin are present in healthy persons.
Methods

Human participants
Peripheral blood mononuclear cells (PBMCs) were obtained from 12 donors, both male and female, ranging in age from 22 to 60 years. Blood was collected and PBMCs were processed, as described previously (36) . Specimens of human fetal spleen and thymus (16-17 weeks of gestation) from elective and/or medically indicated pregnancy terminations were obtained from the Human Fetal Tissue Repository at Albert Einstein College of Medicine of Yeshiva University (Bronx, NY).
Cell separations
For isolating CD39
À or CD25 À T cell populations, PBMCs were first incubated with CD14 microbeads (item 120-001-146; Miltenyi Biotec, San Diego, CA) to remove monocytes that were observed to have high expression of CD39 or that might express CD25. Following monocyte separation, cells were incubated with pan-T cell microbeads (item 120-008-788; Miltenyi Biotec) plus either CD39 microbeads or CD25 microbeads and separated using an autoMACS cell separator (Miltenyi Biotec), according to the manufacturer's protocol. Autologous monocytes were added back to CD39 À or CD25 À T cell fractions at the same frequency as that observed in the whole PBMC sample and used in trans vivo delayedtype hypersensitivity (tvDTH) or intracellular cytokine staining assay systems.
For mouse studies, spleen and bone marrow harvested from 10 to 16 na€ ıve CBA mice from various vendors were used as a source of T cells and monocytes, respectively. Single-cell suspensions of mouse splenocytes were produced, as described previously (12) . For bone marrow harvesting, the tibias and femurs of the mice were cut, and marrow was flushed out with phosphate-buffered saline supplemented with 2% fetal bovine serum (FBS) and 1 mM EDTA. For mouse monocyte separation experiments from the bone marrow, a negative-selection monocyte separation kit from Stemcell Technologies (item 19761; Vancouver, Canada) was used in accordance with the manufacturer's protocol. CD4 + T cells were obtained from mouse splenocytes, using a pan-T cell isolation kit (item 130-095-130; Miltenyi Biotec), according to the manufacturer's instructions. CD25 + T cells were then depleted from isolated CD4 T cell populations by positive CD25 selection (item 130-091-072; Miltenyi Biotec).
tvDTH assay
The tvDTH assay was performed, as described previously (11, 37) . Inactivated tetanus toxoid was purchased from Sanofi Pasteur (Lyon, France) and was used as a positive control antigen for all experiments. Human Col V (5 lg) was a gift from Dr. David Brand (University of Tennessee, Memphis, TN) and was prepared from placenta, as described elsewhere (38 
Statistical analysis
Multiple replicates were averaged across each assay, and data were combined and analyzed by analysis of variance, Mann-Whitney U test, or paired t-test performed with Prism 5.0 (GraphPad Software, La Jolla, CA).
Animal usage and study approval
Informed consent was obtained from human participants using institutional review board (IRB)-approved informed consent procedures at the UW Hospital and clinics. For studies using fetal thymus and spleen, all work was done under approval from the UW-Madison IRB and Albert Einstein College of Medicine, in accordance with federal guidelines. All experiments using blood from mice or rhesus macaques (n = 6) were handled according to animal health and safety guidelines under strict accordance with animal care and use committee and Association for Assessment and Accreditation of Laboratory Animal Care International guidelines.
Results
Col V but not Col I responses are revealed by CD39 or CD25 depletion of T lymphocytes in healthy persons and mice To determine whether Col V-specific cellular immune responses can be found in healthy persons after removal of Tregs, whole PBMCs, total isolated T cells plus monocytes, or CD39 À T cells plus monocyte mixtures were stimulated with Col I or Col V ( Figure 1A ). CB17.SCID mice received footpad injection, and swelling responses were measured 24 h later. In whole PBMCs and in freshly isolated T cell-plus-monocyte mixtures, there was no significant difference (p = 0.14) between the Col I and Col V treatment groups, although a trend toward a higher response to Col V versus Col I was observed. In groups of CD39 À T cells plus monocytes, we observed no increase in the cellular immune response to Col I, but Col V stimulation caused a significant increase (p < 0.001) in the swelling response. Neutralizing antibodies to Th17-associated cytokines, including IL-17 (p < 0.01) and IL-22 (p < 0.02), caused a significant reduction in the cellular immune response to Col V. Adding CD39 + T cells to groups of CD39 À T cells plus monocytes restored the low-Col V response seen in healthy persons. Neutralizing antibodies to IFN-c showed a trend toward inhibition of the Col V response in CD39
À T cell-plus-monocyte groups. When we examined whether the removal of CD25 + T cells could reveal a similar Col V-specific Th17 response in healthy persons ( Figure 1B) , we found that depletion of CD25 + T cells, when combined with autologous monocytes, revealed a Col V-specific cellular immune response that differed significantly (p < 0.01) from the response to Col V in unseparated PBMCs. CD25 + T cell depletion had no effect on the tvDTH response to Col I. The Col V-specific effector response depended on IL-17 (p < 0.02), TNF-a (p < 0.03), and IL-22 (p < 0.03), as indicated by neutralizing antibodies. Neutralizing antibodies to IFN-c showed a trend toward inhibition of the Col V response. To rule out the possibility that a preexisting Th17 memory response to Col V is unique to humans, we investigated whether Treg removal could reveal Col V-specific cellular immune responses in mice. Single-cell suspensions of monocytes isolated from bone marrow were mixed with unfractionated or CD25-depleted T cells isolated from spleens of six to eight CBA mice. Figure 1 (C) illustrates that in whole splenocytes or total T cells plus monocytes, there was no appreciable increase in response to Col V over Col I. In mixtures of CD25 À T cells plus monocytes, however, there was a fourfold increase in the Col V response over that observed in whole splenocytes or total T cells plus monocytes, with no increase in response to Col I.
Col V-specific IL-17 production in CD4 + T cells from healthy persons To identify the cells responsible for the preexisting Col V response, we stimulated overnight cultures of whole PBMCs or CD39 À T cells plus monocytes with Col I or Col V followed by PMA/ionomycin treatment. À T cell-plus-monocyte culture compared with Col I or media control cultures. Although not significant (p = 0.09), there was also a trend toward an increase in IFN-c + CD4 T cells after Col V stimulation in groups of CD39 À T cells plus monocytes, closely paralleling the tvDTH inhibition trend with anti-IFN-c neutralization. We further characterized the IL17 + T cell subset and found that between 40% and 70% of the Th17 cells were also positive for TNF-a, and 15-30% were positive for IL-22 ( Figure 2D ). The IL-17 responders were negative for TCRcd (data not shown). Furthermore, the IL-17-responding population was low in CD161 but positive for ROR ct, PLZF1, and CD45RO.
To define the mechanism by which the CD39 + and CD25 + Tregs control Col V reactivity in healthy persons, we investigated whether blockade of Tregs associated cytokines or surface receptors could reveal a Col V response without the requirement for separation of Treg from Teff subsets. Figure 3 shows that significant Col V responses were revealed in whole PBMCs from healthy persons when TGF-b (p < 0.004), TGF-b-LAP (p < 0.004), or IL-35 (p < 0.008) was neutralized. We observed no significant increase in Col V responses when CTLA4 was blocked or when IL-10 was neutralized. Col V responses were also uncovered in whole PBMCs by the CD39 ATPase inhibitor ARL67156 (2 h pretreatment, 100 lM). À T cell populations were performed from CBA mouse spleens, similar to those described in Methods. Following separations, groups of isolated total T cells plus autologous monocytes and CD25 À T cells plus autologous monocytes along with whole splenocyte samples were stimulated with Col I or Col V and used in the tvDTH assay. Results are from eight pooled mice. Significant differences between groups were determined by Mann-Whitney U tests (A and B) or analysis of variance (C). IFN-c, interferon c; TNF-a, tumor necrosis factor a.
CD39
+ T cell depletion uncovers reactivity to selected autoantigens in healthy persons We next investigated whether, by depleting CD39 + T cells or by TGF-b neutralization, we could uncover T cell responses to other self-proteins besides Col V. compared with unseparated PBMCs (Figure 4C ). Although a trend toward increased IFN-c production in response to ka1-tubulin and vimentin was observed, the differences from the Col I response did not reach statistical significance (p = 0.14) ( Figure 4D ).
Cellular immune responses specific to Col V, ka1-tubulin, and vimentin are present in nonhuman primates To ascertain whether TGF-b-regulated, preexisting cellular immune responses to Col V, ka1-tubulin, and vimentin were evolutionarily conserved between humans and nonhuman primates, we used a TGF-b neutralization and tvDTH approach in PBMCs of healthy rhesus macaques ( Figure 5 ). Whole PBMCs, PBMC plus IgG control, or PBMCs plus aTGF-b were mixed with antigen and injected into the footpads of CB17.SCID mice. Col V (p < 0.02), ka1-tubulin (p < 0.01), and vimentin (p < 0.05) all exhibited a significant increase in footpad swelling in the tvDTH assay ( Figure 5 ). This result was not observed in Col I-stimulated PBMC samples.
Cellular immune responses to Col V, vimentin, and ka1-tubulin appear early in human lymphoid development To investigate the ontogeny of antigen-specific Th17 responses to Col V, ka1-tubulin, and vimentin, we analyzed samples (n = 3) of cryopreserved CD34-depleted human cord blood using the tvDTH assay. In Figure 6 (A), we observed that although Col I, Col V, ka1-tubulin, HSP65, and vimentin responses were low in cord blood, TGF-b neutralization revealed strong responses to Col V, ka1-tubulin, and vimentin. These responses were antigen-specific in that no response to Col I and only a weak response to HSP65 was detected. Furthermore, treatment of cord blood cells with ARL67156 selectively uncovered responses to Col V, ka1-tubulin, and vimentin, suggesting that the cells mediating these responses in the cord blood were not only suppressed by TGF-b but also by downstream products of the CD39 ATPase.
These results implied that preexisting Th17 cells and the corresponding Tregs specific for Col V, ka1-tubulin, and vimentin had developed in utero. We obtained two samples of midgestation-age (16-23 weeks) human thymus and spleen. We used T cell-depleted autologous splenocytes as a source of APCs and mixed them with unseparated thymocytes. No attempt was made to enrich for mature, single, positive CD4 + or CD8 + cells. We observed no response to Col I, Col V, or ka1-tubulin in the unmodified tvDTH assay. In the presence of TGF-bneutralizing antibody, however, we observed a specific increase in the response to Col V and ka1-tubulin but not to Col I. We also examined whether there was antigenspecific IL-17 production from fetal thymocytes in the absence of splenic APCs. We observed an increase in IL-17 among single, positive CD4 T cells from fetal thymocytes depleted of CD25 that were treated with Col V and ka1-tubulin but not Col I ( Figure S1 ).
Th17 cells respond in HLA-DR-restricted fashion to selected fragments of the Col V(a1) chain but not to synthetic 15mer peptides contained therein We previously reported that Col V-reactive patients who are HLA-DR15
À but who have received a DR15 + lung transplant show strong cellular immune responses to DR15 binding synthetic 15mer peptides of the collagenous region of Col V (a1), including peptides p1439, p1049, and p799 (39) . We recently designed and expressed portions of the a1 region of Col V in HEK 293 cells (40) (Figure S2 ). Of the six recombinant fragments of the collagenous region (peptides 551-1581), only fragment 1 contained both a DR1-restricted (p629) and a DQ-restricted (p599) peptide sequence, whereas fragment 5 contained no known DR À or DQ binding peptide (40) . We identified three healthy persons who were HLA-DR15 + and one who served as an HLA-DR1 + -DR15 À control. In Figure 7 , we investigated whether responses to HLA-DR-restricted peptides or fragments of Col V containing these peptides could be revealed by TGF-b neutralization. In Figure 7 (A), the Col V response revealed by TGF-b neutralization in healthy DR15
+ persons (n = 3) was similar in magnitude to that observed without TGF-b neutralization in DR15 + Col V-reactive transplant patients (n = 2). Unlike the Col V-reactive patients, healthy DR15 + persons failed to respond to any synthetic peptide; however, they responded to fragments (2, 4, and 6) containing the DR15 binding peptides. In contrast, the Col V-reactive DR15 + patients responded to the three peptides (p799, p1049, and p1439) predicted to bind DR15 and to fragments 2, 4, and 6. In contrast, the DR1 binding peptide p629, the DQ-binding peptides p909 and p599, fragment 1 (containing peptides p599 and p629), fragment 3 (containing p909), and fragment 5 did not elicit a response ( Figure 7B ).
To investigate whether the restriction pattern was different in HLA-DR1 + healthy persons, we compared PBMCs from a DR1 + Col V-reactive patient with those from a DR1 + healthy person. In the patient, we observed that peptide p629 (DR1 specific) induced a strong response in the tvDTH assay, whereas the DR15-specific peptide p1049 did not. The DQ-binding peptides p599 and p909 each stimulated a weak response. In control DR1 + PBMCs, fragment 1-containing the DR1-specific peptide p629, which had failed to stimulate any response by DR15
+ controls under TGF-b-neutralizing conditions (Figure 7C )-elicited a strong response. Fragment 2, containing the DR1/15 cross-reactive epitope p799, also elicited a strong response in the DR1 + healthy control; however, fragment 4, containing the DR15-specific epitope p1049, and fragment 6, containing the DR1/15 cross-reactive epitope p1439, did not ( Figures 7D-F) . In the patient, we observed that peptide p629 (DR1 specific) induced a strong response in the tvDTH assay, whereas the DR15-specific peptide p1049 did not. The DQ-binding peptides p599 and p909 each stimulated a weak response.
Discussion
Chronic rejection of lung and heart allografts has been associated with an unusual type of autoimmune response in which antibody and T cell responses to ka1-tubulin (lung), vimentin (heart), and Col V (lung and heart) arise in conjunction with the fibro-obliteration of airway and vascular spaces. In the lung, airway obliteration in both mouse and rat allograft models has been shown to depend on IL-17 (41, 42) . The source of the IL-17 driving fibro-obliteration, whether from innate or adaptive T lymphocytes, or both, is still controversial (43) .
In this study, we discovered a preexisting Th17 response to Col V in humans, monkeys, and mice simply by Treg functional blockade or removal. The most straightforward way to demonstrate this phenomenon was by tvDTH assay. This bioassay relies on purinergic and leukotriene signaling between human and mouse leukocytes and readily detects human purinergic receptor-dependent Th17 responses in transplant chronic rejection and atherosclerotic disease (11) (12) (13) (14) (15) . The frequency of IL17 + CD4 T cells that we typically found by PMA/ionomycin stimulation in media-only cultures of whole PBMCs or in T cell-plus-monocyte cultures after CD39 + T cell depletion was 0.2-0.7%-well within the range of the frequency of IL-17-producing CD4 T cells observed by other groups in the healthy population (44) . In addition to this baseline response, after CD39 + T cell depletion, we observed an additional 0.3-0.4% of CD4 T cells producing IL-17 in response to Col V, ka1-tubulin, or vimentin but not to Col I (Figures 2 and 4) . This response, not previously detected in healthy persons, suggests that preexisting Th17 cells specific for the three self-antigens that have been thus far associated with autoimmunity after lung and heart transplantation are in similar frequency in peripheral blood. The similar frequency of cells responsive to Col V, ka1-tubulin, and vimentin in healthy persons likely is not caused by a polyreactive responding CD4 T cell, similar to natural polyreactive B cells responding to self-antigens (45, 46) ; stimulation of fetal thymocytes with both Col V and ka1-tubulin gave IL-17 responses greater than those observed with Col V or ka1-tubulin alone ( Figure S1 ).
Other common self-antigens that have been associated with autoimmune disease, including Col I (scleroderma), Col IV (Goodpasture syndrome), MBP (multiple sclerosis), or cardiac myosin (autoimmune cardiomyopathy), or with an anti-prostate tumor response (PAP) were not included in immune surveillance by this preexisting Th17 system, controlled by the actions of TGF-b (and IL-35) produced by a CD39 + /CD25 + Treg. Cardiac myosin has been identified by Fedoseyeva et al as an autoantigen that triggers an immune response in certain murine heart transplant models (47) . Surprisingly, no preexisting Th17 response to this autoantigen was observed. We attribute this to the predominantly Th1 nature of the anti-cardiac myosin response because Th1 responses may require a dendritic cell as the APC rather than the monocyte APC used in the tvDTH experiment in Figure 4 .
Because Col V responses could be revealed by a specific inhibitor of CD39 À ATPase activity, the Th17-mediated responses to these self-antigens is also likely subject to control by adenosine, a product of the CD39 catalyzed breakdown of extracellular ATP. In addition, the Th17 cell specific for Col V, ka1-tubulin, and vimentin observed throughout this report concomitantly produced the Th17-associated inflammatory cytokine TNF-a (60-80%) as well as IL-22 (20-30%), a cytokine implicated in the repair of damaged epithelial surfaces. Both of these cytokines contributed significantly to the tvDTH footpadswelling response (Figure 1) . The TNF-a/IL-22 findings are similar to those reported in conventional Th17 cells (48) (49) (50) (51) (52) (53) (54) and support the idea that Tregs and Th17 cells may be allies in protecting epithelial surfaces.
In the presence of anti-TGF-b antibody, healthy HLA-DR15 + or HLA-DR1 + persons had no reactivity to synthetic peptides but showed reactivity to intact Col V and to those a1(V) fragments containing the appropriate HLA-DR restricted peptides (Figure 7) . One explanation for this finding is that the Col V-specific Th17 cells we observed in transplant and CAD patients are memory Th17 cells of higher affinity than the ones revealed through Treg depletion or functional blockade in healthy persons. Col V-reactive memory Th17 cells in transplant and CAD patients also likely require a lower threshold of activation versus the antigen-specific preexisting Th17 cells we observed in healthy persons, thereby enabling such T cells to respond to the peptide alone. Alternatively, the preexisting Th17 cells may have similar affinity for peptide/MHC as do Th17 cells from Col V-reactive patients, which do respond to synthetic DR-binding peptides of a1(V). In healthy controls, however, peptides alone provide insufficient stimulation of the APC, resulting in a lack of secondary signaling to the Teff. This secondary signal may be induced in the APC by the T cell in the pathologic setting after peptide recognition that would bypass this requirement.
The data in Figure 6 strongly support the idea that the Th17 cells we observe in healthy persons are thymically differentiated, preexisting Th17 cells because these cells are present in fetal thymus as well as in human cord blood ( Figure 6 ). We hypothesize that preexisting Th17 cells may recognize Col V, ka1-tubulin, or vimentin transiently exposed during normal cycles of injury/repair around airway and vascular structures. As such, they would not chronically be exposed to their target self-antigens, which are subsequently sequestered with major Col I (Col V) or Col II (Col XI) fibrils or within cells (ka1-tubulin and vimentin) during tissue repair.
Zhang et al (55) identified Teffs from human cord blood, including Th1, Th2, and Th17. In this report, it was observed that although effector function for Th1 and Th2 cells was observed without in vitro culture, Th17 cells required 3 days of culture in the presence of Th17-polarizing conditions before they were detectable. This contrasts with our report because we were able to identify Col V, ka1-tubulin, and vimentin responses in cord blood through TGF-b neutralization using the overnight tvDTH assay with no in vitro culture. It should be noted, however, that to detect preexisting Th17 responses in overnight cultures, PMA/ionomycin treatment was required.
The preexisting Th17 responses in CBA mice ( Figure 1 ) and in rhesus macaques ( Figure 5 ) indicate an evolutionarily conserved function of responses to Col V, k-a-1-tubulin, and vimentin. In a previous study, we found that the human HLA-DQ2 and HLA-DQ6 and the mouse DQ equivalent I-A b bound similar a1(V) peptides, p599 and p909, suggesting that the selection of epitopes for DQrestricted responses to Col V by CD4 T cells is also conserved (39) . A possibility is that the maintenance and homeostasis of epithelial or endothelial cell barrier layers mentioned earlier requires the thymus to produce MHC class II-restricted, innate-like T cells. Another is that preservation of commensal micro-organisms needed for proper epithelial function and immune development requires their presence at epithelial interfaces.
In either case, we hypothesize that Th17-mediated pathologies may develop when a preexisting Treg-Th17 balance is lost. A loss of balance may result from chronic exposure of these antigens in the extracellular matrix during repeated infections, atherosclerosis (40) , or the ischemia-reperfusion injury of organ procurement and transplant surgery (38) . A high ratio of extracellular ATP: adenosine, along with standard immunosuppression, may inhibit CD39 + Treg function and allow preexisting Th17 cells to escape from regulatory control. This might select for higher affinity, peripherally induced Th17 clones that are peptide reactive. This possible connection is still unproven. The alternative idea is that pathogenic induced Th17 responses to these self-antigens seen after transplant are completely unrelated to disruption of a preexisting Treg:Th17 homeostasis (56).
Tissue-resident CD4 T cells in the donor organ were recently shown to play a key role in triggering host T follicular helper and B cell responses to vimentin (57) . If the preexisting Treg-Th17 balance of both donor and recipient toward Col V, ka1-tubulin, and vimentin are critical for graft success, and if some DR antigens are better than others at presenting peptides of these three, then the particular DR or DQ antigens expressed by the donor organ may dictate the success of the transplant (39).
In conclusion, we have identified a novel system of preexisting Th17 development present at the time of, and well before, birth. Unlike the thymically derived invariant NK T cell, the preexisting Th17 cell described in this report depends on polymorphic MHC class II-restricted antigen presentation, classically associated with adaptive immunity, while retaining certain features typically associated with innate immunity. Besides its implications for heart and lung transplantation, the results in human, monkey, and mouse provide self-antigen specificity for a subset of preexisting Th17 cells described previously as thymically differentiated T cells that respond rapidly to oral candidiasis and that protect upper airway, lung, and gut mucosa (58, 59) .
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